Related references
Note: Only part of the references are listed.Familial risk of pleural mesothelioma increased drastically in certain occupations: A nationwide prospective cohort study
Elham Kharazmi et al.
EUROPEAN JOURNAL OF CANCER (2018)
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Vasiliki Panou et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
Sebastian Walpole et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes
Marta Betti et al.
GENES CHROMOSOMES & CANCER (2018)
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations
Sandra Pastorino et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Jutija Hmeljaki et al.
CANCER DISCOVERY (2018)
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types
Arielle L. Heeke et al.
JCO PRECISION ONCOLOGY (2018)
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair
Rossella Parrotta et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma
Marta Betti et al.
CANCER LETTERS (2017)
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Gayathri Srinivasan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma
Ellen T. Chang et al.
CANCER CAUSES & CONTROL (2017)
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer
Jill A. Ohar et al.
CANCER RESEARCH (2016)
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
A. Napolitano et al.
ONCOGENE (2016)
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
M. Betti et al.
CANCER LETTERS (2016)
Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations
Yuwaraj Kadariya et al.
CANCER RESEARCH (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist et al.
JAMA ONCOLOGY (2016)
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Clare L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Francine Baumann et al.
CARCINOGENESIS (2015)
A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma
K. A. W. Wadt et al.
CLINICAL GENETICS (2015)
Germline Mutations in Shelterin Complex Genes Are Associated With Familial Glioma
Matthew N. Bainbridge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
POT1 loss-of-function variants predispose to familial melanoma
Carla Daniela Robles-Espinoza et al.
NATURE GENETICS (2014)
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Germline BAP1 Mutations Predispose to Renal Cell Carcinomas
Tatiana Popova et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2013)
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma
Jaine K. Blayney et al.
EUROPEAN JOURNAL OF CANCER (2012)
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Kelly L. Bolton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
Mohamed H. Abdel-Rahman et al.
JOURNAL OF MEDICAL GENETICS (2011)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew Bott et al.
NATURE GENETICS (2011)
Germline mutations in BAP1 predispose to melanocytic tumors
Thomas Wiesner et al.
NATURE GENETICS (2011)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa et al.
NATURE GENETICS (2011)
Erionite exposure in North Dakota and Turkish villages with mesothelioma
Michele Carbone et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. William Harbour et al.
SCIENCE (2010)
Medical progress - Advances in malignant mesothelioma
BWS Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Pot1, the putative telomere end-binding protein in fission yeast and humans
P Baumann et al.
SCIENCE (2001)
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
